Overview of prostate biomarkers as potential targets for immunotherapy

Current Cancer Therapy Reviews

Volumn 4, Issue 2, 2008, Pages 86-95

  Miles, Amanda K ^a   Roger, Alistair ^a,b   Parkinson, Richard ^b   Rees, Robert C ^a   McArdle, Stephanie E B ^a  

^a NOTTINGHAM TRENT UNIVERSITY   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Immunotherapy; Peptides; Prostate; SEREX; T21

Indexed keywords

EID: 54749116538     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339408784310034     Document Type: Review

References (77)

1. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries. BJU Int 2002; 90(2): 174-184.
2. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 2002; 90(2): 162-173.
3. Simons J, Mikhak B, Chang J, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumour cells engineered to secrete granulocyte-macrophage colony stimulating factor using ex-vivo gene transfer. Cancer Res 1999; 59(20): 5160-5168.
4. Guidelines on the management of prostate cancer. A document for local expert groups in the United Kingdom preparing prostate management policy documents. The Royal College of Radiologists' Clinical Oncology Information Network. British Association of Urological Surgeons. BJU Int 1999; 84: 987-1014.
5. Hrouda D, Todryk S, Perry M, et al. Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer. BJU Int 2000; 86(6): 742-748.
6. Eaton J, Perry M, Nicholson S, et al. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer. BJU Int 2002; 89(1): 19-26.
7. Murphy G, Tjoa B, Simmons S, et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999; 38(1): 73-78.
8. Murphy G, Tjoa B, Simmons S, et al. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999; 39: 54-59.
9. Small E, Fratesi P, Reese D, Strang G, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18(23): 3894-3903.
10. Meidenbauer N, Harris D, Spitler L, Whiteside T. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 2000; 43(2): 88-100.
11. Moss DJ, Schmidt C, Elliott S, Suhrbier A, Burrows S, Khanna R. Strategies involved in developing an effective vaccine for EBV-associated diseases. Adv Cancer Res 1996; 69: 213-245.
12. Kawashima I, Hudson S, Tsai V, et al. The multi-epitope approach for immunotherapy for cancer identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 1998; 59(1): 1-14.
13. Thomson S, Elliot S, Sherritt M, et al. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J Immunol 1996; 157: 822-826.
14. Murphy GP. Prostate cancer: here and now. CA Cancer J Clin 1995; 45(3): 133.
15. Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 1997; 57(12): 2321-2324.
16. Watt KW, Lee PJ, M'Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986; 83(10): 3166-3170.
17. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17(2): 159-163.
18. Liu H, Mov P, Kim S, et al. Monoclonal antibodies to the extracellular domain at prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997; 57(17): 3629-3634.
19. Bander NH. Current status of monoclonal antibodies for imaging and therapy of prostate cancer. Semin Oncol 1994; 21(5): 607-612.
20. Hubert RS, Vivanco I, Chen E, et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci USA 1999; 96(25): 14523-14528.
21. Gregor PD, Wolchok JD, Turaga V, et al. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer 2005; 116(3): 415-421.
22. Steiner MS. Transforming growth factor-beta and prostate cancer. World J Urol 1995; 13(6): 329-336.
23. Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995; 46(5): 681-686.
24. Labarthe MC, Halanek N, Birchall L, et al. The biological effects of syngeneic and allogeneic cytokine-expressing prophylactic whole cell vaccines and the influence of irradiation in a murine melanoma model. Cancer Immunol Immunother 2006; 55(3): 277-88.
25. Saffran D, Reiter R, Jakobovits A, Witte O. Target antigens for prostate cancer immunotherapy. Cancer Metastasis Rev 1999; 18(4): 437-449.
26. Jacobs EL, Haskell CM. Clinical use of tumor markers in oncology. Curr Probl Cancer 1991; 15(6): 299-360.
27. Quintero IB, Araujo CL, Pulkka AE, et al. Prostatic acid phosphatase is not a prostate specific target. Cancer Res 2007; 67(14): 6549-54.
28. Peshwa M, Shi J, Ruegg C, Laus R, Schooten WV. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 1998; 36(2): 129-138.
29. McNeel D, Nguyen L, Disis M. Identification of T helper epitopes from prostatic acid phosphatase. Cancer Res 2000; 61(13): 5161-5167.
30. Drijfhout J, Brandt R, D'Amaro J, Kast W, Melief C. Detailed motifs for peptide binding to HLA-A* 0201 derived from large random sets of peptides using a cellular binding assay. Hum Immunol 1995; 43: 1-12.
31. Kawashima I, Hudson S, Tsai V, et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 1998; 59(1): 1-14.
32. Peshwa MV, Shi JD, Ruegg C, Laus R, van Schooten WC. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 1998; 36(2): 129-138.
33. Small E, Fratesi P, Reese D, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18(23): 3894-3903.
34. Meidenbauer N, Harris D, Spitler L, Whiteside T. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 2000; 43(2): 88-100.
35. Sette A, Vitiello A, Reherman B, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994; 153(12): 5586-5592.
36. Heukamp LC, van der Burg SH, Drijfhout JW, Melief CJ, Taylor-Papadimitriou J, Offringa R. Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective and-tumor immunity in HLA-A2/K(b)-transgenic mice. Int J Cancer 2001; 91(3): 385-392.
37. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA. Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 1995; 92(26): 11993-11997.
38. Vitiello A, Marchesini D, Furze J, Sherman LA, Chesnut RW. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med 1991; 173(4): 1007-1015.
39. Machlenkin A, Paz A, Bar Haim E, et al. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Cancer Res 2005; 65(14): 6435-6442.
40. Machlenkin A, Azriel-Rosenfeld R, Volovitz I, et al. Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice. Cancer Immunol Immunother 2007; 56(2): 217-226.
41. Schalken JA, Hessels D, Verhaegh G. New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology 2003; 62(5 Suppl 1): 34-43.
42. Stephan C, Yousef GM, Scorilas A, et al. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol 2004; 171(1): 187-91.
43. Srikantan V, Valladares M, Rhim JS, Moul JW, Srivastava S. HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res 2002; 62(23): 6812-6.
44. Magee JA, Araki T, Patil S, et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001; 61(15): 5692-6.
45. Landers KA, Burger MJ, Tebay MA, et al. Use of multiple biomarkers for a molecular diagnosis of prostate cancer. Int J Cancer 2005; 114(6): 950-6.
46. Lin B, Ferguson C, White JT, et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res 1999; 59(17): 4180-4.
47. Yoshimoto M, Joshua AM, Chilton-Macneill S, et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia 2006; 8(6): 465-9.
48. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2: ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006; 66(7): 3396-400.
49. Ahlers CM, Figg WD. ETS-TMPRSS2 fusion gene products in prostate cancer. Cancer Biol Ther 2006; 5(3): 254-5.
50. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310(5748): 644-8.
51. Luo J, Zha S, Gage WR, et el. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002; 62(8): 2220-6.
52. Magi-Galluzzi C, Luo J, Isaacs WB, Hicks JL, de Marzo AM, Epstein JL. Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy. Am J Surg Pathol 2003; 27(8): 1128-33.
53. Evans AJ. Alpha-methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies. J Clin Pathol 2003; 56(12): 892-7.
54. Rubin MA, Zhou M, Dhanasekaran SM, et al. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002; 287(13): 1662-70.
55. Kristiansen G, Pilarsky C, Wissmann C, et al. ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 2003; 54(1): 34-43.
56. Kristiansen G, Pilarsky C, Wissmann C, et al. Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival. J Pathol 2005; 205(3): 359-76.
57. King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG. Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res 2004; 6(5): R478-87.
58. Weichert W, Knosel T, Bellach J, Dietel M, Kristiansen G. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 2004; 57(11): 1160-4.
59. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92(25): 11810-3.
60. Sahin U, Li G, Tureci O, Pfreundschuh M. Recognition of human tumors: SEREX expression cloning to identify tumour antigens. In: Robins RA, Rees RC, editor. Cancer Immunology. Dordrecht/Boston/London: Kluwer Academic Publishers 2001; pp. 45-57.
61. Tureci O, Sahin U, Pfreundschuh M. Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today 1997; 3(8): 342-9.
62. Old LJ, Chen YT. New paths in human cancer serology. J Exp Med 1998; 187(8): 1163-7.
63. Line A, Slucka Z, Stengrevics A, Li G, Rees RC. Altered splicing pattern of TACC1 mRNA in gastric cancer. Cancer Genet Cytogenet 2002; 139(1): 78-83.
64. Line A, Stengrevics A, Slucka Z, Li G, Jankevics E, Rees RC. Serological identification and expression analysis of gastric cancer-associated genes. Br J Cancer 2002; 86(11): 1824-30.
65. Line A, Slucka Z, Stengrevics A, Silina K, Li G, Rees RC. Characterisation of tumour-associated antigens in colon cancer. Cancer Immunol Immunother 2002; 51(10): 574-82.
66. Tureci O, Sahin U, Schobert I, et al. The SSX-2 gene, which is involved in the t(X; 18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res 1996; 56(20): 4766-72.
67. Obata Y, Takahashi T, Tamaki H, et al. Identification of cancer antigens in breast cancer by the SEREX expression cloning method. Breast Cancer 1999; 6(4): 305-311.
68. Scanlan MJ, Gordan JD, Williamson B, et al. Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer 1999; 83(4): 456-64.
69. Liu HY, Peng LP, Ran YL, et al. [Screening and identification of human lung cancer-related antigens]. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao 2002; 34(2): 171-5.
70. Miles AK, Rogers A, Li G, et al. Identification of a novel prostate cancer-associated tumor antigen. Prostate 2007; 67(3): 274-87.
71. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254(5038): 1643-7.
72. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S. et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94(5): 1914-8.
73. Ono T, Kurashige T, Harada N, Noguchi Y, Saika T, Niikawa N, et al. Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. Proc Natl Acad Sci USA 2001; 98(6): 3282-7.
74. Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 2003; 162 (6): 1807-15.
75. Skotheim RI, Kraggerud SM, Fossa SD, et al. Familial/bilateral and sporadic testicular germ cell tumors show frequent genetic changes at loci with suggestive linkage evidence. Neoplasia 2001; 3(3): 196-203.
76. Schmidt H, Taubert H, Wurl P, et al. Gains of 12q are the most frequent genomic imbalances in adult fibrosarcoma and are correlated with a poor outcome. Genes Chromosomes Cancer 2002; 34(1): 69-77.
77. Zitzelsberger H, Kulka U, Lehmann L, et al. Genetic heterogeneity in a prostatic carcinoma and associated prostatic intraepithelial neoplasia as demonstrated by combined use of laser-microdissection, degenerate oligonucleotide primed PCR and comparative genomic hybridization. Virchows Arch 1998; 433(4): 297-304.